ArticleJournal of ovarian research2026
BRD4-associated chromatin remodelling signature links epigenetic regulation to immune landscape in ovarian cancer.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundChromatin remodelling-related genes (CRRGs) are essential regulators of gene expression and tumour behaviour. Their role in shaping the immune microenvironment and influencing prognosis in ovarian cancer (OV) remains largely unexplored. We develop a CRRG-based prognostic signature and investigate its association with immune infiltration, particularly plasmacytoid dendritic cells (pDCs).
methodsWe integrated transcriptomic and clinical data from The Cancer Genome Atlas (TCGA; n = 228) and the International Cancer Genome Consortium (ICGC; n = 111) OV cohorts. Differentially expressed CRRGs associated with overall survival were identified and used to construct a prognostic signature via least absolute shrinkage and selection operator and Cox regression. Immune infiltration was analysed using single-sample gene set enrichment analysis (ssGSEA) and validated by multiplex immunofluorescence (mIF). Correlations between CK7+BRD4 expression, pDC infiltration, and chemokine profiles were assessed using public databases and clinical specimens.
resultsAn 11-gene CRRG-based immune-associated signature was established, effectively stratifying patients into high- and low-risk groups with significantly different overall survival in both cohorts. The risk score was an independent prognostic factor. Immune analyses revealed that high-risk patients exhibited reduced pDC infiltration and lower activation of antigen presentation-related pathways. BRD4 was identified as a key gene negatively correlated with the pDC levels across datasets. High BRD4 expression was associated with poor survival and decreased expression of multiple pDC-attracting chemokines. mIF staining confirmed the inverse correlation between CK7+BRD4 expression and BDCA2+ pDC infiltration in OV tumour tissues.
conclusionOur study proposes a novel CRRG-based prognostic signature linked to the immune features in OV and highlights BRD4 as a potential regulator of pDC infiltration through the suppression of chemokine expression. These findings provide insights into the interplay between epigenetic regulation and the immune landscape in OV, although the implications for immunotherapy responsiveness warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.